Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylsulfonylmethane
- Development stage
- Phase 3
- Lead developer
- Balchem
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Methylsulfonylmethane (MSM) is a naturally occurring organosulfur compound widely used as a dietary supplement for its anti-inflammatory and antioxidant properties. It is the oxidized form of dimethyl sulfoxide (DMSO). MSM is primarily investigated for its efficacy in reducing joint pain and inflammation associated with osteoarthritis, often in combination with glucosamine or chondroitin. Mechanistically, it has been shown to inhibit NF-kappa B activation and the NLRP3 inflammasome, thereby reducing the production of pro-inflammatory cytokines such as IL-6 and TNF-alpha. Additionally, research suggests potential benefits in cardiometabolic health, exercise recovery, and metabolic-associated fatty liver disease (MAFLD) through the modulation of AMPK/mTOR signaling pathways.
- Brand names
- OptiMSM
- Other names
- MSMdimethyl sulfoneDMSO2DMSO-2DMSO 2methyl sulfone
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)mTOR (Mammalian target of rapamycin kinase)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on methylsulfonylmethane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylsulfonylmethane.